☆ 4.1 Review

The role of delamanid in the treatment of drug-resistant tuberculosis

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2015)

期刊

THERAPEUTICS AND CLINICAL RISK MANAGEMENT

卷 11, 期 -, 页码 779-791

出版社

DOVE MEDICAL PRESS LTD

DOI: 10.2147/TCRM.S71076

关键词

delamanid; OPC-67683; tuberculosis; drug resistance; MDR-TB

类别

Health Care Sciences & Services

向作者/读者索取更多资源

Protocol

Reagent

摘要

Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Chemistry, Medicinal

Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host-Directed Therapies

Pobitra Borah, Pran Kishore Deb, Katharigatta N. Venugopala, Nizar A. Al-Shar'i, Vinayak Singh, Satyendra Deka, Amavya Srivastava, Vinod Tiwari, Raghu Prasad Mailavaram

Summary: Human tuberculosis is primarily caused by Mycobacterium tuberculosis and presents a complex disease with factors like reactivation of latent form, disease progression in immunocompromised patients, emergence of drug-resistant strains, and drug interactions. New anti-TB drugs are needed to overcome these obstacles, and scientific advancements have revolutionized diagnosis, prevention, and treatment, but there are still knowledge gaps and challenges to address in future TB control programs.

CURRENT TOPICS IN MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Editorial Material Immunology

Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid

Takashi Yoshiyama, Akiko Takaki, Akio Aono, Satoshi Mitarai, Masao Okumura, Ken Ohta, Seiya Kato

Summary: This study reported a clinical case of simultaneous acquisition of resistance to bedaquiline and delamanid in Mycobacterium tuberculosis, with specific nucleotide insertions identified through whole genome sequencing. The minimum inhibitory concentrations for bedaquiline and delamanid were determined to be 0.25 μg/mL and >2.0 μg/mL, respectively.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Prevalence of Multidrug-Resistant TB Among Smear-Positive Pulmonary TB Patients in Banadir, Somalia: A Multicenter Study

Abdirahman Mohamed Hassan Dirie, Sedat Colakoglu, Osman Muhyadin Abdulle, Bashir Mohamud Abdi, Mohamed Abdi Osman, Abdiaziz Mohamud Shire, Abdinafic Mohamud Hussein

Summary: The study found a prevalence of MDR-TB among pulmonary TB patients in Banadir, Somalia, which is similar to some eastern African countries.

INFECTION AND DRUG RESISTANCE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches

Amit Kumar, Bidhu Bhusan Karkara, Gautam Panda

Summary: This article summarizes the importance of developing new drugs for tuberculosis, current research directions and efforts, and aims to provide assistance in designing new chemical entities (NCEs) for Mtb.

CHEMICAL BIOLOGY & DRUG DESIGN (2021)

添加到收藏夹

Article Infectious Diseases

Early mortality during rifampicin-resistant TB treatment

E. Mohr-Holland, J. Daniels, A. Reuter, C. A. Rodriguez, C. Mitnick, Y. Kock, V Cox, J. Furin, H. Cox

Summary: This study found that the use of LZD/BDQ/DLM between 2012 and 2019 can reduce the 6-month mortality rate of rifampicin-resistant tuberculosis patients. However, there was no significant effect overall, which may be due to the initially restricted use of LZD/BDQ/DLM for patients with high-level resistance or treatment failure.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid

Katherine A. Abrahams, Sarah M. Batt, Sudagar S. Gurcha, Natacha Veerapen, Ghader Bashiri, Gurdyal S. Besra

Summary: This study identifies an enzyme required for the synthesis of the mycobacterial cell wall as the target of Pretomanid and delamanid, two pro-drugs used for tuberculosis treatment. The findings provide valuable insights into the mechanisms of action and potential clinical applications of these drugs.

NATURE COMMUNICATIONS (2023)

添加到收藏夹

Article Infectious Diseases

Multidrug-resistant tuberculosis in children: Are the same therapy options available worldwide?

Danilo Buonsenso, Giovanni Autore, Francesca Cusenza, Lucrezia Passadore, Francesca Bonanno, Susanna Esposito

Summary: The spread of drug-resistant tuberculosis (TB) has led to the development of new drugs and the reappraisal of old drugs. Ensuring access to child-friendly medicines for drug-resistant TB is crucial for reducing the global burden of TB. This perspective highlights the need for child-friendly formulations of second-line drugs to improve adherence to treatment regimens and prevent the development of additional drug resistance.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent

Wei Luo, Zhigang Huang, Deming Xu, Meng Yang, Yusong Zhu, Liang Shen, Shuhui Chen, Xin Tao, Wang Bin, Yinghu Hu, Scott G. Franzblau, Ning Jiang, Yuquan Wei, Xiawei Wei, Charles Z. Ding

Summary: Multidrug-resistant pulmonary tuberculosis (MDR-TB) is a global health problem. Current approved nitroimidazoles for MDR-TB treatment have limitations, leading to the need for safer alternatives. In the search for such an alternative, JBD0131 was discovered, demonstrating excellent antimycobacterial activity and improved pharmacokinetics and absorption compared to existing drugs.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)

添加到收藏夹

Article Microbiology

Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates

Kone Kaniga, Rumina Hasan, Ruwen Jou, Edita Vasiliauskiene, Charoen Chuchottaworn, Nazir Ismail, Beverly Metchock, Skaidrius Miliauskas, Nguyen Viet Nhung, Camilla Rodrigues, Soyoun Shin, Hulya Simsek, Saijai Smithtikarn, Anh Le Thi Ngoc, Jirakan Boonyasopun, Mubin Kazi, Seungmo Kim, Phalin Kamolwat, Greta Musteikiene, Catherine Ann Sacopon, Sabira Tahseen, Laima Vasiliauskaite, Mei-Hua Wu, Shaheed Vally Omar

Summary: Bedaquiline Drug Resistance Emergence Assessment in Multidrug-resistant tuberculosis (MDR-TB) (DREAM) conducted a 5-year surveillance study across 11 countries, finding low resistance rates to Bedaquiline and no treatment-limiting patterns of cross-resistance or coresistance with key TB drugs.

JOURNAL OF CLINICAL MICROBIOLOGY (2022)

添加到收藏夹

Article Microbiology

The ddn Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis

Mikael Mansjo, Oskar Karlsson Lindsjo, Christina Gronfors Seeth, Ramona Groenheit, Jim Werngren

Summary: This study reports that the ddn mutation Trp20Stop is exclusively found among DLM and Pa resistant isolates assigned to lineage 4.5 in the Swedish strain collection, indicating the rarity of high-confidence resistance mutations for new and repurposed anti-TB drugs.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Respiratory System

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

S. Koirala, S. Borisov, E. Danila, A. Mariandyshev, B. Shrestha, N. Lukhele, M. Dalcolmo, S. R. Shakya, S. Miliauskas, L. Kuksa, S. Manga, A. Aleksa, J. T. Denholm, H. B. Khadka, A. Skrahina, S. Diktanas, M. Ferrarese, J. Bruchfeld, A. Koleva, A. Piubello, G. S. Koirala, Z. F. Udwadia, D. J. Palmero, M. Munoz-Torrico, R. Gc, G. Gualano, V. Grecu, I Motta, A. Papavasileiou, Y. Li, W. Hoefsloot, H. Kunst, J. Mazza-Stalder, M-C Payen, O. W. Akkerman, E. Bernal, V Manfrin, A. Matteelli, H. Mustafa Hamdan, M. Nieto Marcos, J. Cadinanos Loidi, J. J. Cebrian Gallardo, R. Duarte, N. Escobar Salinas, R. Gomez Rosso, R. Laniado-Laborin, E. Martinez Robles, S. Quiros Fernandez, A. Rendon, I Solovic, M. Tadolini, P. Viggiani, E. Belilovski, M. J. Boeree, Q. Cai, E. Davidaviciene, L. D. Forsman, J. De Los Rios, J. Draksiene, A. Duga, S. E. Elamin, A. Filippov, A. Garcia, I Gaudiesiute, B. Gavazova, R. Gayoso, V Gruslys, J. Jonsson, E. Khimova, G. Madonsela, C. Magis-Escurra, V Marchese, M. Matei, C. Moschos, B. Nakceriene, L. Nicod, F. Palmieri, A. Pontarelli, A. Smite, M. B. Souleymane, M. Vescovo, R. Zablockis, D. Zhurkin, J-W Alffenaar, J. A. Caminero, L. R. Codecasa, J-M Garcia-Garcia, S. Esposito, L. Saderi, A. Spanevello, D. Visca, S. Tiberi, E. Pontali, R. Centis, L. D'Ambrosio, M. van den Boom, G. Sotgiuw, G. B. Migliori

Summary: The study evaluated the effectiveness of bedaquiline and/or delamanid-containing regimens in consecutively treated TB patients globally. The majority of severely drug-resistant patients achieved treatment success, but a portion died or were lost to follow-up.

PULMONOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid

Anna Bateson, Julio Ortiz Canseco, Timothy D. McHugh, Adam A. Witney, Silke Feuerriegel, Matthias Merker, Thomas A. Kohl, Christian Utpatel, Stefan Niemann, Sonke Andres, Katharina Kranzer, Florian P. Maurer, Arash Ghodousi, Emanuele Borroni, Daniela Maria Cirillo, Maria Wijkander, Juan C. Toro, Ramona Groenheit, Jim Werngren, Diana Machado, Miguel Viveiros, Robin M. Warren, Frederick Sirgel, Anzaan Dippenaar, Claudio U. Koeser, Eugene Sun, Juliano Timm

Summary: The study reveals ancient differences in susceptibility to pretomanid among different lineages of Mycobacterium tuberculosis complex (MTBC) and recent emergence of resistance. The findings highlight the significance of considering global diversity of MTBC in clinical drug development and defining breakpoints for antimicrobial susceptibility testing.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

添加到收藏夹

Article Biology

An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in Mycobacterium tuberculosis

Victoria Furio, Miguel Moreno-Molina, Alvaro Chiner-Oms, Luis M. Villamayor, Manuela Torres-Puente, Inaki Comas

Summary: Victoria Furio et al. used functional genomics and evolutionary analyses to study antibiotic resistance in tuberculosis, identifying novel candidate genes with resistance mutations in clinical strains and uncovering the mechanisms underlying drug resistance.

COMMUNICATIONS BIOLOGY (2021)

添加到收藏夹

Article Microbiology

Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models

Rokeya Tasneen, Andrew Garcia, Paul J. Converse, Matthew D. Zimmerman, Veronique Dartois, Ekaterina Kurbatova, Andrew A. Vernon, Wendy Carr, Jason E. Stout, Kelly E. Dooley, Eric L. Nuermberger

Summary: A recent trial showed that a 4-month regimen of rifapentine, pyrazinamide, moxifloxacin, and isoniazid is as effective as the standard 6-month treatment. Novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug demonstrated increased sterilizing activity in mouse models of tuberculosis.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Evaluation of risk factors associated with the development of MDR- and XDR-TB in a tertiary care hospital: a retrospective cohort study

Amna Saifullah, Tauqeer Hussain Mallhi, Yusra Habib Khan, Muhammad Shahid Iqbal, Nasser Hadal Alotaibi, Abdulaziz Ibrahim Alzarea, Maria Rasheed

Summary: The study revealed a significant number of resistant cases among pulmonary TB patients, with females, young adults, unemployed individuals, smokers, patients with previous treatment failure, and those with cavitation on chest X-ray showing a substantial risk for DR-TB.

PEERJ (2021)

添加到收藏夹

Article Critical Care Medicine

Forgiveness Is the Attribute of the Strong: Nonadherence and Regimen Shortening in Drug-sensitive Tuberculosis

Helen R. Stagg, Jennifer A. Thompson, Marc C. Lipman, Derek J. Sloan, Mary Flook, Katherine L. Fielding

Summary: This study aimed to determine the impact of regimen length, drugs, dosing, and nonadherence timing on the forgiveness of antituberculosis regimens. The results showed that shorter 4-month regimens were just as forgiving as the standard 6-month regimen and did not differ in terms of nonadherence tolerance. The study also found evidence of mediation by continuation phase dose-taking on the relationship between intensive phase dose-taking and negative outcome.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Article Immunology

Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin

Christine Sekaggya-Wiltshire, Ruth Nabisere, Joseph Musaazi, Brian Otaalo, Florence Aber, Lucy Alinaitwe, Juliet Nampala, Letisha Najjemba, Allan Buzibye, Denis Omali, Kamunkhwala Gausi, Allan Kengo, Mohammed Lamorde, Rob Aarnoutse, Paolo Denti, Kelly E. Dooley, Derek J. Sloan

Summary: This study found that high-dose rifampicin can reduce the concentrations of dolutegravir and efavirenz in HIV patients without compromising virological suppression. It is well tolerated among people with HIV and associated with a trend toward faster sputum culture conversion.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Infectious Diseases

Clinical features and management of individuals admitted to hospital with monkeypox and associated complications acrossthe UK: a retrospective cohort study

Douglas L. Fink, Helen Callaby, Akish Luintel, William Beynon, Helena Bond, Eleanor Y. Lim, Effrossyni Gkrania-Klotsas, Jospeh Heskin, Margherita Bracchi, Balram Rathish, Iain Milligan, Geraldine O'Hara, Stephanie Rimmer, Joanna R. Peters, Lara Payne, Nisha Mody, Bethany Hodgson, Penny Lewthwaite, Rebecca Lester, Stephen D. Woolley, Ann Sturdy, Ashley Whittington, Leann Johnson, Nathan Jacobs, John Quartey, Brendan A. Payne, Stewart Crowe, Ivo A. M. Elliott, Thomas Harrison, Joby Cole, Katie Beard, Tomas-Paul Cusack, Imogen Jones, Rishi Banerjee, Tommy Rampling, Jake Dunning

Summary: The 2022 global mpox outbreak has been unprecedented, with over 67,000 cases reported in non-endemic countries. Although mortality is rare, hospital admission is relatively common. This study found that males, white ethnicity, and HIV-infected patients were more likely to be hospitalized, and severe pain and secondary bacterial infection were the main reasons for admission.

LANCET INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Infectious Diseases

Unravelling patient pathways in the context of antibacterial resistance in East Africa

Katherine L. Keenan, Kathryn J. G. Fredricks, Mary Abed I. Al Ahad, Stella T. Neema, Joseph R. Mwanga, Mike Kesby, Martha F. Mushi, Annette E. Aduda, Dominique L. Green, Andy G. Lynch, Sarah I. Huque, Blandina T. Mmbaga, Hannah Worthington, Catherine Kansiime, Emmanuel Olamijuwon, Nyanda E. Ntinginya, Olga Loza, Joel Bazira, Antonio H. Maldonado-Barragan, VAnne Smith, Arun Gonzales Decano, John Mwaniki J. Njeru, Alison B. Sandeman, John Stelling, Alison E. Elliott, David Aanensen, Stephen H. Gillespie, Gibson Kibiki, Wilber Sabiiti, Derek J. Sloan, Benon B. Asiimwe, John Kiiru, Stephen E. T. Mshana, Matthew T. G. Holden

Summary: This study investigates the patterns and determinants of patient treatment-seeking pathways and their intersection with antibiotic use in East Africa. The findings reveal that patients often follow multi-step treatment pathways, and patients with higher socioeconomic status are more likely to consume antibiotics. The choice of healthcare services is influenced by factors such as cost, location, and time. The study recommends improving healthcare systems, including accessible diagnostics, patient-doctor interactions, information flows, and strengthened regulation of drug sellers.

BMC INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

Antibiotic dispensing practices during COVID-19 and implications for antimicrobial resistance (AMR): parallel mystery client studies in Uganda and Tanzania

Emmanuel Olamijuwon, Eveline Konje, Catherine E. Kansiime, Mike F. Kesby, Katherine Keenan, Stella Neema, Benon Asiimwe, Stephen J. Mshana, Martha Mushi, Olga R. Loza, Benjamin Sunday, Alison Sandeman, Derek Sloan, Fernando Benitez-Paez, Joseph Mwanga, Wilber Sabiiti, Matthew T. G. Holden

Summary: This study explores the drug seller-client interaction and antibiotic dispensing patterns for simulated COVID-19 symptoms in Tanzania and Uganda. The findings indicate low adherence to COVID-19 preventive measures, dispensing of prescription-only antibiotics without prescription, and providing incomplete doses of antibiotics by drug sellers.

ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2023)

添加到收藏夹

Review Genetics & Heredity

A systematic review of economic evaluations of whole- genome sequencing for the surveillance of bacterial pathogens

Vivien Price, Lucky Gift Ngwira, Joseph M. Lewis, Kate S. Baker, Sharon J. Peacock, Elita Jauneikaite, Nicholas Feasey

Summary: This article summarizes the economic analyses of genomic surveillance of bacterial pathogens, and all studies support the use of whole-genome sequencing as an economically viable surveillance tool.

MICROBIAL GENOMICS (2023)

添加到收藏夹

Article Genetics & Heredity

Genomic analysis of extended- spectrum beta- lactamase (ESBL) producing Escherichia coli colonising adults in Blantyre, Malawi reveals previously undescribed diversity

Joseph M. Lewis, Madalitso Mphasa, Rachel Banda, Mathew A. Beale, Jane Mallewa, Catherine Anscome, Allan Zuza, Adam P. Roberts, Eva Heinz, Nicholas R. Thomson, Nicholas A. Feasey

Summary: This study investigated ESBL-producing E. coli colonizing adults in Blantyre, Malawi to assess bacterial diversity and AMR determinants. The results showed that 37% of the Malawian isolates did not cluster with isolates from other countries, indicating local transmission. Additionally, a globally distributed carbapenemase-carrying plasmid was found in a single isolate. The study concludes that as carbapenem use increases, there is a risk of rapid proliferation of carbapenem resistance in E. coli in Malawi, highlighting the importance of antimicrobial stewardship and genomic surveillance.

MICROBIAL GENOMICS (2023)

添加到收藏夹

Article Infectious Diseases

Investigating One Health risks for human colonisation with extended spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Malawian households: a longitudinal cohort study

Derek Cocker, Kondwani Chidziwisano, Madalitso Mphasa, Taonga Mwapasa, Joseph M. Lewis, Barry Rowlingson, Melodie Sammarro, Winnie Bakali, Chifundo Salifu, Allan Zuza, Mary Charles, Tamandani Mandula, Victor Maiden, Stevie Amos, Shevin Jacob, Henry Kajumbula, Lawrence Mugisha, David Musoke, Rachel Byrne, Thomas Edwards, Rebecca Lester, Nicola Elviss, Adam P. Roberts, Andrew C. Singer, Christopher Jewell, Tracy Morse, Nicholas Feasey

Summary: The prevalence of ESBL-producing Enterobacterales is extremely high in humans, animals, and the environment in southern Malawi. Urbanization and seasonality are significant risk factors for colonization, and without proper environmental improvements, transmission of ESBL-producing bacteria is likely to persist in this setting.

LANCET MICROBE (2023)

添加到收藏夹

Article Infectious Diseases

It is not easy: Experiences of people living with HIV and tuberculosis on Tuberculosis treatment in Uganda

Ruth Nabisere-Arinaitwe, Lydia Namatende-Sakwa, Josephine Bayiga, Juliet Nampala, Lucy Alinaitwe, Florence Aber, Brian Otaalo, Joseph Musaazi, Rachel King, Mike Kesby, Derek J. Sloan, Christine Sekaggya-Wiltshire

Summary: In order to achieve patient-centered tuberculosis (TB) care, it is important to understand patient experiences and perceptions. This study found that patients were more concerned about medication adverse effects that clinicians sometimes overlook, and reasons for self-prescribing medications included difficulties in accessing medical practitioners. Barriers to treatment adherence included stigma, pill size and number, and discomfort with medication formulation and adverse effects. Therefore, tailored pre-treatment counselling, improved access to clinical services, and simpler drug administration can deliver more patient-centered care.

JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania

Stellah G. G. Mpagama, Happiness C. C. Mvungi, Peter M. M. Mbelele, Hadija H. H. Semvua, Alphonce A. A. Liyoyo, Kristen Petros de Guex, Derek Sloan, Gibson S. S. Kibiki, Martin Boeree, Patrick P. J. Phillips, Scott K. K. Heysell

Summary: This study is a proof-of-concept clinical trial designed to explore the potential protective effect of N-acetylcysteine (NAC) in patients with multidrug resistant tuberculosis (MDR-TB) using second-line anti-TB medications. The trial aims to determine if NAC reduces adverse drug reactions (ADRs) and if this protection is dose-dependent.

PILOT AND FEASIBILITY STUDIES (2023)

添加到收藏夹

Article Microbiology

Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin

Allan Kengo, Kamunkhwala Gausi, Ruth Nabisere, Joseph Musaazi, Allan Buzibye, Denis Omali, Rob Aarnoutse, Mohammed Lamorde, Kelly E. Dooley, Derek James Sloan, Christine Sekaggya-Wiltshire, Paolo Denti

Summary: This study characterized the pharmacokinetics of rifampicin in Ugandan adults with tuberculosis and HIV, taking different doses and antiretroviral therapy. The results showed a 4.7-fold increase in exposure between high and standard doses, which was lower than what previous reports predicted. The lower bioavailability of the rifampicin-only top-up formulation compared to the fixed-dose combination was identified as the reason.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

The role of multidimensional poverty in antibiotic misuse: a mixed-methods study of self-medication and non-adherence in Kenya, Tanzania, and Uganda

Dominique L. Green, Katherine Keenan, Kathryn J. Fredricks, Sarah Huque, Martha F. Mushi, Catherine Kansiime, Benon Asiimwe, John Kiiru, Stephen E. Mshana, Stella Neema, Joseph R. Mwanga, Mike Kesby, Andy G. Lynch, Hannah Worthington, Emmanuel Olamijuwon, Mary Abed Al Ahad, Annette Aduda, John Mwaniki Njeru, Blandina T. Mmbaga, Joel Bazira, Alison Sandeman, John Stelling, Stephen H. Gillespie, Gibson Kibiki, Wilber Sabiiti, Derek J. Sloan, Matthew T. G. Holden, the H. A. T. U. A. Consortium HATUA Consortium

Summary: This study investigated the relationship between multidimensional poverty and antibiotic use in patient populations in Kenya, Tanzania, and Uganda. The results showed that regardless of poverty status, structural barriers such as inefficiencies in public health care, financial constraints, and unregulated antibiotic access contribute to antibiotic misuse and treatment non-adherence. When designing interventions to reduce antibiotic misuse and address antimicrobial resistance, greater attention should be paid to these structural barriers.

LANCET GLOBAL HEALTH (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

Trial-of-antibiotics to assist tuberculosis diagnosis in symptomatic adults in Malawi (ACT-TB study): a randomised controlled trial

Titus H. Divala, Elizabeth L. Corbett, Chikondi Kandulu, Brewster Moyo, Peter MacPherson, Marriott Nliwasa, Neil French, Derek J. Sloan, Lingstone Chiume, Masiye John Ndaferankhande, Sanderson Chilanga, Sabina Tazirwa Majiga, Jon oyvind Odland, Katherine L. Fielding

Summary: This study compared the diagnostic performance, clinical benefit, and antimicrobial resistance of trial-of-antibiotics with standard care in individuals with symptom improvement. The results show that trial-of-antibiotics modestly improved the diagnostic specificity for mycobacteriologically confirmed tuberculosis, but had no appreciable effect on clinical outcomes.

LANCET GLOBAL HEALTH (2023)

添加到收藏夹

Article Biology

Localization and phenotyping of tuberculosis bacteria using a combination of deep learning and SVMs

Marios Zachariou, Ognjen Arandjelovic, Evelin Dombay, Wilber Sabiiti, Bariki Mtafya, Nyanda Elias Ntinginya, Derek J. Sloan

Summary: In this study, a method for automated detection of lipid content and dimensions of tuberculosis bacteria using microscopy images was proposed. The use of an adapted UNet model and a feature extractor improved the performance of bacterial detection compared to previous methods, and accurate estimation of length and width of bacteria was achieved.

COMPUTERS IN BIOLOGY AND MEDICINE (2023)

添加到收藏夹

Article Microbiology

High Mycobacterium tuberculosis Bacillary Loads Detected by Tuberculosis Molecular Bacterial Load Assay in Patient Stool: a Potential Alternative for Nonsputum Diagnosis and Treatment Response Monitoring of Tuberculosis

Emmanuel Musisi, Abdul Sessolo, Sylvia Kaswabuli, Josephine Zawedde, Patrick Byanyima, Shariifah Kasinga, Ingvar Sanyu, Esther Uwimaana, Stanley Walimbwa, Joseph Olore, Willy Ssengooba, Christine Sekaggya, Moses L. Joloba, William Worodria, Laurence Huang, Stephen H. Gillespie, Derek J. Sloan, Wilber Sabiiti

Summary: This study investigates the use of stool as an alternative sample type for tuberculosis diagnosis. By using TB-MBLA, an RNA-based quantitative test, to detect and quantify Mycobacterium tuberculosis in stool samples, the study demonstrates the potential of stool as a substitute for sputum in tuberculosis diagnostics, particularly for individuals who have difficulty producing sputum. Additionally, compared to culture-based traditional methods, TB-MBLA shows higher accuracy in detecting and quantifying tuberculosis bacteria in stool.

MICROBIOLOGY SPECTRUM (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.